Published in Ann Intern Med on July 16, 2002
Histoplasmosis: a clinical and laboratory update. Clin Microbiol Rev (2007) 6.41
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care (2013) 3.40
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis (2012) 1.41
Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay. Clin Vaccine Immunol (2011) 1.22
Improved detection of Histoplasma antigenemia following dissociation of immune complexes. Clin Vaccine Immunol (2009) 1.18
Fungal infections in intensive care unit: challenges in diagnosis and management. Ann Med Health Sci Res (2013) 1.09
Histoplasmosis in HIV-Infected Patients: A Review of New Developments and Remaining Gaps. Curr Trop Med Rep (2014) 1.06
Imported acquired immunodeficiency syndrome-related histoplasmosis in metropolitan France: a comparison of pre-highly active anti-retroviral therapy and highly active anti-retroviral therapy eras. Am J Trop Med Hyg (2011) 0.92
An instructive case of CNS histoplasmosis in an immunocompetent host. Med Mycol Case Rep (2012) 0.89
Section 4: Contrast-induced AKI. Kidney Int Suppl (2011) (2012) 0.82
continuous versus conventional infusion of amphotericin B deoxycholate: a meta-analysis. PLoS One (2013) 0.81
Synthesis and antifungal activity in vitro of isoniazid derivatives against histoplasma capsulatum var. capsulatum. Antimicrob Agents Chemother (2014) 0.79
Section 3: Prevention and Treatment of AKI. Kidney Int Suppl (2011) (2012) 0.78
Role of diuretics and lipid formulations in the prevention of amphotericin B-induced nephrotoxicity. Eur J Clin Pharmacol (2013) 0.78
Incidence, Predictors, and Impact on Hospital Mortality of Amphotericin B Nephrotoxicity Defined Using Newer Acute Kidney Injury Diagnostic Criteria. Antimicrob Agents Chemother (2015) 0.77
Amphotericin B lipid complex: treatment of invasive fungal infections in patients refractory to or intolerant of amphotericin B deoxycholate. Ther Clin Risk Manag (2008) 0.77
Antifungal clinical trials and guidelines: what we know and do not know. Cold Spring Harb Perspect Med (2014) 0.75
Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs (2016) 0.75
Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized. Philos Trans R Soc Lond B Biol Sci (2016) 0.75
Intravitreal liposomal amphotericin B for treatment of endogenous candida endophthalmitis. Jpn J Ophthalmol (2015) 0.75
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis (2009) 18.19
Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america. Clin Infect Dis (2010) 11.65
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med (2008) 8.50
Guidelines for treatment of candidiasis. Clin Infect Dis (2003) 5.55
Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis (2010) 5.53
Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clin Infect Dis (2007) 5.51
Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother (2003) 5.48
Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis (2010) 4.98
Tuberculosis. N Engl J Med (2013) 4.75
A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis (2003) 4.29
Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med (2003) 3.92
Distribution of health care expenditures for HIV-infected patients. Clin Infect Dis (2006) 3.72
Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol (2007) 3.29
Voriconazole: a new triazole antifungal agent. Clin Infect Dis (2003) 3.19
Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis (2012) 3.09
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment. AIDS (2009) 2.91
Use of central venous catheter-related bloodstream infection prevention practices by US hospitals. Mayo Clin Proc (2007) 2.90
A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis (2003) 2.84
Detection of histoplasma antigen by a quantitative enzyme immunoassay. Clin Vaccine Immunol (2007) 2.81
Magnetic resonance imaging screening to identify spinal and paraspinal infections associated with injections of contaminated methylprednisolone acetate. JAMA (2013) 2.74
An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients. Am J Respir Crit Care Med (2011) 2.70
Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. Clin Infect Dis (2008) 2.55
Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr (2004) 2.55
Blood (1->3)-beta-D-glucan as a diagnostic test for HIV-related Pneumocystis jirovecii pneumonia. Clin Infect Dis (2011) 2.54
A multicenter evaluation of tests for diagnosis of histoplasmosis. Clin Infect Dis (2011) 2.50
Renal disease in an antiretroviral-naïve HIV-infected outpatient population in Western Kenya. Nephrol Dial Transplant (2007) 2.45
Gastrointestinal histoplasmosis. Am J Gastroenterol (2005) 2.43
Preventing hospital-acquired urinary tract infection in the United States: a national study. Clin Infect Dis (2008) 2.42
Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America. Clin Infect Dis (2008) 2.35
Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis (2003) 2.20
Oral acyclovir suppression and neurodevelopment after neonatal herpes. N Engl J Med (2011) 2.18
Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clin Infect Dis (2004) 2.17
Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis (2013) 2.16
Home intravenous antimicrobial infusion therapy: a viable option in older adults. J Am Geriatr Soc (2007) 2.16
Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis (2010) 2.15
Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis (2009) 2.13
Safety of budesonide inhalation suspension in infants aged six to twelve months with mild to moderate persistent asthma or recurrent wheeze. J Pediatr (2005) 2.09
Incomplete immune reconstitution after initiation of highly active antiretroviral therapy in human immunodeficiency virus-infected patients with severe CD4+ cell depletion. J Infect Dis (2003) 2.04
Nontuberculous pyogenic spinal infection in adults: a 12-year experience from a tertiary referral center. Spine (Phila Pa 1976) (2006) 2.00
Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr (2002) 1.98
Association of upper trunk and visceral adipose tissue volume with insulin resistance in control and HIV-infected subjects in the FRAM study. J Acquir Immune Defic Syndr (2007) 1.98
Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis. Clin Infect Dis (2005) 1.95
Vancomycin-resistant enterococcal colonization and infection in liver transplant candidates and recipients: a prospective surveillance study. Clin Infect Dis (2005) 1.93
Histoplasmosis. Infect Dis Clin North Am (2003) 1.89
MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clin Infect Dis (2014) 1.78
Epidemiology of Staphylococcus aureus colonization in nursing home residents. Clin Infect Dis (2008) 1.72
Prevalence of inducible clindamycin resistance among community- and hospital-associated Staphylococcus aureus isolates. J Clin Microbiol (2006) 1.71
Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol (2007) 1.71
Indwelling device use and antibiotic resistance in nursing homes: identifying a high-risk group. J Am Geriatr Soc (2007) 1.70
Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis (2003) 1.69
Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis (2005) 1.68
Patterns of susceptibility of Aspergillus isolates recovered from patients enrolled in the Transplant-Associated Infection Surveillance Network. J Clin Microbiol (2009) 1.68
Introduction of a waterless alcohol-based hand rub in a long-term-care facility. Infect Control Hosp Epidemiol (2003) 1.67
Switching effective antiretroviral therapy: a review. Clin Infect Dis (2002) 1.66
Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother (2005) 1.61
Changing epidemiology of rare mould infections: implications for therapy. Drugs (2007) 1.59
Plasmalyte as a cause of false-positive results for Aspergillus galactomannan in bronchoalveolar lavage fluid. J Clin Microbiol (2006) 1.58
Treatment of endogenous fungal endophthalmitis: focus on new antifungal agents. Clin Infect Dis (2011) 1.57
Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis (2004) 1.57
A randomized study of the use of fluconazole in continuous versus episodic therapy in patients with advanced HIV infection and a history of oropharyngeal candidiasis: AIDS Clinical Trials Group Study 323/Mycoses Study Group Study 40. Clin Infect Dis (2005) 1.56
Duration of highly active antiretroviral therapy regimens. Clin Infect Dis (2003) 1.50
Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus disease. J Infect Dis (2008) 1.49
Diagnosis of coccidioidomycosis by antigen detection using cross-reaction with a Histoplasma antigen. Clin Infect Dis (2007) 1.49
Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. Am J Respir Crit Care Med (2003) 1.47
Candida urinary tract infections--epidemiology. Clin Infect Dis (2011) 1.47
Activity of newer triazoles against Histoplasma capsulatum from patients with AIDS who failed fluconazole. J Antimicrob Chemother (2006) 1.46
New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis (2012) 1.46
The HIV protease inhibitor ritonavir blocks osteoclastogenesis and function by impairing RANKL-induced signaling. J Clin Invest (2004) 1.45
Antifungal therapy and length of hospitalization in transplant patients with invasive aspergillosis. Med Mycol (2012) 1.44
Zygomycosis: reemergence of an old pathogen. Clin Infect Dis (2004) 1.43
Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis (2005) 1.43
Recognition and prevention of nosocomial invasive fungal infections in the intensive care unit. Crit Care Med (2010) 1.41
Effect of adenine arabinoside on severe Herpesvirus hominis infections in man. 1973. J Infect Dis (2004) 1.39
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med (2011) 1.37
Pulmonary fungal infections. Respirology (2012) 1.36
Invasive non-Aspergillus mold infections in transplant recipients, United States, 2001-2006. Emerg Infect Dis (2011) 1.34
Neurodevelopmental outcomes following ganciclovir therapy in symptomatic congenital cytomegalovirus infections involving the central nervous system. J Clin Virol (2009) 1.32
Differences in histoplasmosis in patients with acquired immunodeficiency syndrome in the United States and Brazil. J Infect Dis (2002) 1.30
Test performance of blood beta-glucan for Pneumocystis jirovecii pneumonia in patients with AIDS and respiratory symptoms. AIDS (2013) 1.23
Reducing plasma HIV RNA improves muscle amino acid metabolism. Am J Physiol Endocrinol Metab (2004) 1.22
Histoplasma antigen clearance during treatment of histoplasmosis in patients with AIDS determined by a quantitative antigen enzyme immunoassay. Clin Vaccine Immunol (2011) 1.22